Development of Antidrug Antibodies on Bulevirtide Monotherapy in Chronic Hepatitis Delta Does Not Impact Bulevirtide Efficacy, Safety, or Pharmacokinetics

Conference Reports for NATAP

AASLD
The Liver Meeting
November Fri, Nov 10, 2023 - Mon, Nov 14, 2023


Development of Antidrug Antibodies on Bulevirtide Monotherapy in Chronic Hepatitis Delta Does Not Impact Bulevirtide Efficacy, Safety, or Pharmacokinetics

	AASLD 2023 nov 10-14 https://www.aasld.org/the-liver-meeting